MarketFriction

Sanofi India Ltd

NSE SANOFI · BSE 500674 · Pharmaceuticals
₹3,037.40 -0.64%
NSE close2026-10-01
52 week range3,049.00 - 4,898.00
Market cap₹7,075 Cr.
P/E20.6
Price band 20% Delivery 59.1%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales491469511464524515536406475420472438
Expenses377370374348404397364311341330330322
Operating Profit1141001371161201181729513490143115
OPM %23%21%27%25%23%23%32%23%28%22%30%26%
Other Income8277412121439-22346
Interest000000000100
Depreciation999991010991099
Profit before tax1861671691271131221659410283138112
Tax %18%18%19%19%27%25%28%26%26%26%26%26%
Net Profit152138137103829112070766210384
EPS in Rs66.1759.8759.3944.9635.7439.7051.9630.2233.0426.8344.6136.30
Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025TTM
Sales2,1932,3672,4602,7713,0712,9022,9572,7702,8512,0131,8371,805
Expenses1,8171,8321,9212,1462,4032,1862,1942,0662,0471,5221,3461,323
Operating Profit376535538625667716762704804491491483
OPM %17%23%22%23%22%25%26%25%28%24%27%27%
Other Income21866798833455642048379-8-9
Interest021102222222
Depreciation11311910210310082674240373736
Profit before tax4814805156106006771,258864846531445436
Tax %33%37%37%38%31%29%25%28%29%22%27%
Net Profit322304326381414478944621603414327324
EPS in Rs139.78132.26141.74165.48180.09207.65410.61269.83262.26179.78142.04140.78
Dividend Payout %46%51%50%51%194%176%119%211%64%65%87%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth-2%-9%-13%-9%
Compounded Profit Growth3%-7%-13%-4%
Stock Price CAGR2%-9%-11%-34%
Return on Equity26%37%48%43%
Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025Jun 2026
Equity Capital232323232323232323232323
Reserves1,6041,8602,0032,1962,4192,0962,2031,253992838726803
Borrowings0000023252419191815
Other Liabilities778658751765802777811772681732488567
Total Liabilities2,4052,5412,7782,9843,2442,9183,0612,0721,7151,6121,2551,407
Fixed Assets877817769733499464334306315312304291
CWIP223430211710132416181219
Investments000000002000
Other Assets1,5051,6901,9782,2302,7282,4442,7141,7431,3821,2819391,098
Total Assets2,4052,5412,7782,9843,2442,9183,0612,0721,7151,6121,2551,407
Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Cash from Operating Activity265213322435374412611559399231462438
Cash from Investing Activity6136-155-79-736627663165136-178-11
Cash from Financing Activity-122-147-180-188-197-183-810-849-1,583-878-392-448
Net Cash Flow205102-1316810429578341-533-612-109-21
Free Cash Flow247184253379317337810574412221426413
CFO/OP114%93%101%118%99%96%112%111%94%59%114%111%
Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Debtor Days212422292127191817174235
Inventory Days179173169151154127107110125202186127
Days Payable1228179119110100931051098915179
Cash Conversion Cycle781151126165543322331307783
Working Capital Days26979171835-8-20-1924177
ROCE %22%26%27%26%29%28%32%35%41%71%49%58%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%
FIIs6.80%6.31%6.11%5.81%5.78%5.64%5.58%5.61%5.57%5.55%5.65%5.69%
DIIs21.68%22.51%22.88%22.60%22.62%22.94%23.02%23.06%22.28%21.30%21.12%19.87%
Public11.10%10.78%10.61%11.21%11.20%11.04%11.01%10.94%11.75%12.75%12.84%14.05%
No. of Shareholders68,59862,87061,84967,66266,21166,40168,19666,79071,39575,81375,75880,005

Fundamentals

Market Cap₹ 7,075 Cr.
Current Price₹ 3,072
Stock P/E20.6
Book Value₹ 359
ROCE57.5 %
ROE43.0 %
Dividend Yield2.44 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-9%
Compounded Profit Growth (TTM)-4%
Standalone figures.
Valuation
Market capRs 6,995 Cr
Enterprise valueRs 6,738 Cr
P/E (TTM)21.60x
Price to book9.34x
Price to sales3.88x
EV / EBITDA14.23x
EV / EBIT15.42x
EV / sales3.73x
Price to cash flow15.96x
Earnings yield4.63%
Dividend yield4.04%
P/E, 3-year average27.27x
P/B, 3-year average13.39x
P/E, 5-year average21.39x
P/B, 5-year average10.33x
Profitability
Operating margin (excl. other income)26.74%
Operating margin (incl. other income)26.33%
EBITDA margin26.24%
Pre-tax margin24.12%
Net profit margin17.94%
Net margin, latest quarter19.08%
ROE40.59%
ROCE54.21%
ROA22.79%
ROE, 3-year average45.77%
ROCE, 3-year average60.83%
ROA, 3-year average26.50%
ROE, 5-year average43.25%
ROCE, 5-year average57.73%
ROA, 5-year average27.06%
ROIC (approx.)65.25%
Tax rate26.53%
Other income / net worth-1.01%
Growth
Sales growth (latest year)-8.73%
Profit growth (latest year)-20.99%
Sales CAGR, 3 years-12.79%
Sales CAGR, 5 years-8.73%
Profit CAGR, 3 years-19.26%
Profit CAGR, 5 years-7.31%
Sales growth QoQ-7.33%
Profit growth QoQ-18.62%
Sales growth YoY (latest quarter)7.73%
Profit growth YoY (latest quarter)20.14%
Per share
EPS (TTM)Rs 140.60
EPS (latest year)Rs 141.85
EPS (latest quarter)Rs 36.26
EPS, 3-year averageRs 194.44
EPS, 5-year averageRs 252.57
Book value per shareRs 325.31
Sales per shareRs 783.83
Cash flow per shareRs 190.31
Free cash flow per shareRs 179.33
Dividend per share (latest year)Rs 122.84
Dividend per share, 3-year averageRs 135.49
Dividend per share, 5-year averageRs 293.01
Dividends
Dividend payout86.59%
Dividend payout, 3-year average71.78%
Dividend payout, 5-year average109.19%
Efficiency
Asset turnover1.46x
Fixed asset turnover6.04x
Inventory turnover3.00x
Inventory days122 days
Debtor days35 days
Debtors turnover10.40x
Creditor days79 days
Cash conversion cycle83 days
Working capital days7 days
Leverage
Total debtRs 18 Cr
Cash and bankRs 275 Cr
Net debtRs -257 Cr
Debt to equity0.02x
Net debt / EBITDA-0.54x
Interest coverage273.19x
Current ratio (filing 2026-06-30)1.90x
Quick ratio (filing 2026-06-30)1.35x
Trade payables (filing 2026-06-30)Rs 274 Cr
Owners' fund to total sources59.71%
Debt to assets1.42%
Cash flow
Cash from Operating Activity (latest year)Rs 438 Cr
Cash from Investing Activity (latest year)Rs -11 Cr
Cash from Financing Activity (latest year)Rs -448 Cr
Net Cash Flow (latest year)Rs -21 Cr
Free cash flow (latest year)Rs 413 Cr
FCFE (approx.: FCF + change in debt)Rs 412 Cr
Cash from ops / profit, 5 years0.72x
Sales to cash flow4.19x
Statement figures
Net sales (TTM)Rs 1,805 Cr
Net sales (latest year)Rs 1,837 Cr
Sales (latest quarter)Rs 438 Cr
Operating profit excl. other income (latest year)Rs 491 Cr
Operating profit (latest quarter)Rs 115 Cr
Other income (TTM)Rs -9 Cr
EBITDA (TTM)Rs 474 Cr
PBDT (TTM)Rs 472 Cr
Profit before tax (TTM)Rs 436 Cr
Tax (latest year)Rs 118 Cr
Net profit (TTM)Rs 324 Cr
Net profit (latest year)Rs 327 Cr
Net profit (latest quarter)Rs 84 Cr
Depreciation (TTM)Rs 36 Cr
Depreciation (latest quarter)Rs 9 Cr
Interest (TTM)Rs 2 Cr
Cost of goods sold (latest year)Rs 934 Cr
Total expenditure (latest year)Rs 1,346 Cr
Total income (latest year)Rs 1,830 Cr
Share capitalRs 23 Cr
ReservesRs 726 Cr
Shareholders' fundsRs 749 Cr
Total assetsRs 1,255 Cr
Net blockRs 304 Cr
Capital work in progressRs 12 Cr
ReceivablesRs 177 Cr
InventoryRs 312 Cr
Other liabilitiesRs 488 Cr
Shares outstanding (crore)2.30
Ownership
Promoter holding60.40% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 21.6 is at the 13th percentile of its own 9.7-year range (median 32.7, low 13.4, high 48.0).
P/B 9.34 is at the 61th percentile (median 7.80).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodSANOFINifty 50Difference
1 week-3.0%-2.8% -0.3 pts
1 month-3.7%-6.8% +3.1 pts
3 months-11.3%-7.6% -3.7 pts
6 months-5.4%+0.4% -5.8 pts
1 year-37.8%-9.9% -27.9 pts
2 years-57.9%-13.6% -44.3 pts
3 years-57.9%+14.2% -72.0 pts
5 years-61.4%+27.9% -89.3 pts
22 mutual fund schemes hold about ₹628 Cr. Over three months 7 bought more and 7 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Nippon India Small Cap Fund0.18%150 -2%
Aditya Birla SL Large Cap Fund0.36%106 +37%
Nippon India Pharma Fund0.99%94 +29%
SBI Contra Fund0.17%79 +3%
Nippon India Growth Mid Cap Fund0.11%57 -3%
Aditya Birla SL Balanced Advantage Fund0.40%40 +27%
Abakkus Small Cap Fund1.05%29 -4%
Quant Small Cap Fund0.06%20 -4%
Bandhan Flexi Cap Fund0.22%17 +910%
Nippon India Innovation Fund0.42%13 -18%
Bandhan Multi Asset Allocation Fund0.21%8 +100%
Tata Ethical Fund0.18%7 -2%
Bandhan Healthcare Fund1.51%5 +34%
Sundaram Dividend Yield Fund0.44%4 +5%
Bandhan BSE Healthcare Index Fund0.17%0 -0%
Motilal Oswal BSE 1000 Index Fund0.01%0 +5%
Aditya Birla SL Consumption Fund0.00%0 -100%
SBI ELSS Tax Saver Fund0.00%0 -100%
Tata India Pharma & Healthcare Fund0.00%0 -100%
Aditya Birla SL Dividend Yield Fund0.00%0 -100%
Aditya Birla SL Aggressive Hybrid Fund0.00%0 -100%
Aditya Birla SL MNC Fund0.00%0 -100%

Red flags

F-score 7 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2026-09-24Hoechst GmbHPromoter groupsell3,500,000SAST Inter-se transfer
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹438 Cr +7.9% vs Jun 2025. Net profit ₹84 Cr +20.0%.
Against our estimate for Jun 2026: sales +27.2%, profit +46.8% beat. Our estimate for Sep 2026: sales Rs 465 Cr, profit Rs 82 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-04-22Dividend - Rs 48 Per Share
2025-11-07Interim Dividend - Rs 75 Per Share
2025-04-25Dividend - Rs 117 Per Share
2024-06-13Demerger
2024-05-03Dividend - Rs 117 Per Share
2024-05-03Annual General Meeting
2024-03-07Interim Dividend - Rs 50 Per Share
2023-04-28Final Dividend - Rs 194/ Special Dividend - Rs 183 Per Share
2022-08-05Special Dividend - Rs 193 Per Sh
2022-04-12Annual General Meeting/Dividend - Rs 181 Per Share/Special Dividend - Rs 309 Per Share
2021-04-19 Dividend - Rs 125 Per Share Special Dividend 240 Per Share
2020-06-29 Dividend - Rs 106 Per Share Special Dividend 243 Per Share
2019-04-25 Annual General Meeting / Dividend - Rs 66 Per Share
2018-08-06 Interim Dividend -Rs 18 Per Share
2018-04-26 Annual General Meeting/ Dividend - Rs 53 Per Share
2017-07-31 Interim Dividend-Rs 18/- Per Share
2017-04-25 Annual General Meeting/Dividend Rs 50/- Per Share
2016-08-04 Interim Dividend - Rs 18/- Per Share
2016-04-13 Final Dividend - Rs 25/- Per Share + Special Dividend - Rs 22/- Per Share
2015-07-29Interim Dividend - Rs 18/- Per Share (Purpose Revised)
2015-04-16Annual General Meeting / Final Dividend - Rs 24/- Per Share / Special One-Time Dividend - Rs 11/- Per Share
2014-07-31Interim Dividend - Rs 10/- Per Share
2014-04-16Annual General Meeting/Dividend Rs 35/- Per Share
2013-08-05Interim Dividend Rs.10/- Per Share (Purpose Revised)
2013-04-05Annual General Meeting/Dividend Rs 29 Per Share
2012-08-02Interim Dividend Rs.4/- Per Share (Purpose Revised)
2012-04-10Annual General Meeting And Dividend Rs.29/- Per Share
2011-08-03Interim Dividend Rs 4 Per Share (Purpose Revised)
2011-03-31Annual General Meeting And Dividend - Final - Rs.23/- And Special - Rs.28/- Per Share
2010-07-26Interim Dividend Rs.4/- Per Share (Purpose Revised)
2010-04-07Agm/Div-Rs.16.50 Pr Share
2009-07-30Int Div-Rs.3.50 Per Sharepurpose Revised
2009-04-06Agm/Div-Rs.12.50 Per Shre
2008-07-29Int Div-Rs.3.50 Per Sharepurpose Revised
2008-04-03Agm/Div-Rs12.50 Per Share
2007-07-25Int Div-Rs.3.50 Per Sh Purpose Revised
2007-06-01Agm
2007-03-22Div Int-Rs12.50+Spl-Rs16 Purpose Revised
2006-08-03Int Div-Rs.3.50/- Per Sh Purpose Revised
2006-05-19Agm/Div-Rs.12.50/- Per Sh
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Order dateForumCase
2021-02-15NCLTSanofi India Ltd vs Sandor Medicaids Pvt Ltd Vs
2021-01-18NCLTSanofi India Ltd vs Sandor Medicaids Pvt Ltd Vs
2020-11-03NCLTSanofi India Ltd vs Sandor Medicaids Pvt Ltd Vs
2020-10-09NCLTSanofi India Ltd vs Sandor Medicaids Pvt Ltd Vs
Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Sanofi India Ltd?

Sanofi India Ltd (SANOFI) has a market capitalisation of Rs 7,075 Cr. at the 2026-10-01 close.

What is the P/E ratio of Sanofi India Ltd?

Sanofi India Ltd trades at a P/E of 20.6 on trailing twelve-month profit, at the 2026-10-01 close.

What were Sanofi India Ltd's latest quarterly results?

In the Jun 2026 quarter, Sanofi India Ltd sales was Rs 438 Cr (+7.9% vs Jun 2025) and net profit was Rs 84 Cr.

What is the 52-week high and low of Sanofi India Ltd?

The 52-week high is Rs 4,898.00 and the 52-week low is Rs 3,049.00.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03